Skin involvement due to a systemic infection with Aspergillus species in the course of allogeneic hematopoietic cell transplantation is extremely rare. We report the clinical course of two patients with hematologic malignancies who underwent allogeneic hematopoietic cell transplantation (HCT) and developed disseminated skin involvement as the first clinical symptom of a proven systemic Aspergillus infection. Bone Marrow Transplantation (2001) 27, 753-755. Keywords: cutaneous Aspergillus infection; HCT; BMT; STX; skin infection Aspergillus species are increasingly recognized as major fungal pathogens in severely immunosuppressed or neutropenic patients, particularly after allogeneic hematopoietic cell transplantation (HCT).
Aspergillus species are increasingly recognized as major fungal pathogens in severely immunosuppressed or neutropenic patients, particularly after allogeneic hematopoietic cell transplantation (HCT). 1 The risk of developing systemic Aspergillus infection increases with the duration of immunosuppression. The most common manifestation of an Aspergillus infection in these patients is invasive pulmonary aspergillosis characterized by hyphal invasion and destruction of pulmonary tissue. 2, 3 Hematogenous dissemination as a secondary event occurs in 20-50% of these patients and most commonly involves the central nervous system and the gastrointestinal tract. 4 The overall mortality is up to 82% and reflects the clinical importance of Aspergillus infection in immunosuppressed or neutropenic patients. 5 Solitary extrapulmonary Aspergillus infection occurs most frequently in the maxillary sinuses 6, 7 and colonization of the nasal sinuses can lead to endogenous spread to the lungs causing invasive pulmonary aspergillosis. The skin is a rare site of infection, 8 and cutaneous infections are most often found at the entry site of Hickman catheters. 4, 7, 9, 10 Cutaneous aspergillosis is a poorly described entity among hematopoietic cell recipients. 11 Here, we describe the clinical course of two patients after allogeneic HCT, who developed skin involvement as primary manifestation of systemic aspergillosis.
Case report No. 1
A 50-year-old male with Philadelphia-positive chronic myeloid leukemia in accelerated phase received a non-T cell-depleted bone marrow graft (1.2 × 10 8 MNC/kg BW) from his HLA-identical, MLC-negative brother. He was conditioned with busulfan (10 mg/kg), thiotepa (750 mg/kg) and cyclophosphamide (120 mg/kg) and received methotrexate and cyclosporine as GVHD prophylaxis. On day −1 twice daily prophylactic aerosol inhalation of 10 mg amphotericin B was started. On day +2 he developed fever of unknown origin and was empirically treated with a combination of cefotaxim, piperacillin and vancomycin. Because there was no resolution of the fever, intravenous (i.v.) amphotericin B was started at a dose of 0.8 mg/kg/day on day +4. On day +9 a round warm red swelling resembling a small furuncle appeared on the right thigh. This lesion grew rapidly and was extremely painful. On day +13 this lesion measured approximately 5 cm in diameter and in the centre a circular area of necrosis, 2 cm in diameter, had developed ( Figure 1 ). Until that time microbiological examination of multiple blood cultures had yielded no positive result. Necrotic tissue from the lesion on the right thigh was sent for microbiological culture and histological examination. Both microbiological and histological examination were negative. On day +15 additional, similar lesions appeared on the right shoulder and the right cheek. On day +16 Aspergillus fumigatus was isolated from smears from the lesions on the right thigh and right shoulder. The dose of amphotericin B was increased to 1.5 mg/kg/day i.v. On day +17, invasive pulmonary aspergillosis was suspected because of severe chest pain, dyspnea and tachypnea. Conventional chest X-ray at that time, however, was normal. His temperature was 38.4°C, sublingually the leukocyte count was 30 × 10 9 /l, the C-reactive protein 13.0 mg/dl and the latex agglutination test for Aspergillus-antigen was negative. The patient died on day +18 from intrapulmonary hemorrhage.
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Case report No 2
A 41-year-old man suffering from Philadelphia chromosome-positive chronic myeloid leukemia in first chronic phase was given a matched unrelated peripheral blood stem cell transplant (1.78 × 10 6 CD34-positive cells/kg BW). The conditioning regimen consisted of busulfan (12.4 mg/kg i.v.), cyclophosphamide (200 mg/kg) and ATG (10 mg/kg). Because of graft failure, a second transplant was carried out 4 weeks later (1.6 × 10 6 CD34-positive cells/kg BW). Conditioning for this second transplant was performed with an anti-T lymphocyte monoclonal antibody (OKT 3) and methylprednisolone. This time, engraftment was achieved on day +11. High-resolution computed tomography of the lungs carried out to monitor for pulmonary CMV infection was normal. The patient developed acute graft-versus-host reaction of the skin grade II on day +22 after the second transplant and treatment with 2 mg/kg prednisolone was instituted. On day +26, livid painful skin nodules, some with central necrosis, developed on the trunk and thighs despite the improved general condition of the patient (Figure 2 ). The number and size of these nodules increased rapidly. Aspergillus flavus was identified from a cutaneous biopsy. Although systemic antimycotic treatment with amphotericin B at a dose of 1 mg/kg/day i.v. for 2 days was started immediately, the skin nodules rapidly progressed. Since the patient did not tolerate amphotericin B, he was switched to liposomal amphotericin B at a dose of 3 mg/kg/day i.v. for 7 days. With the administration of voriconazole at a dose of 300 mg/day for 2 days administered on a compassionate basis, the nodules became pale and also regressed. However, the patient died on day +39 after the second transplant and 14 days after the appearance of the first cutaneous nodules. Autopsy confirmed the clinical diagnosis of systemic aspergillosis with extensive involvement of the heart, the lungs, the kidneys and the skin.
Discussion
We describe the clinical course of two patients with skin manifestation of a systemic Aspergillus infection. In the literature two types of cutaneous Aspergillus infections are described: primary cutaneous Aspergillus infection caused by direct infection of the skin and secondary cutaneous Aspergillus infection in the course of hematogenic dissemination of systemic aspergillosis. Most reports of cutaneous aspergillosis deal with primary skin infections. In these reports local trauma or skin maceration caused by adhesive tapes as well as surgical wounds, for instance caused by indwelling catheters or implantation of contaminated foreign material, play a major pathogenic role. 4, 9 Secondary cutaneous dissemination of aspergillosis in immunosuppressed patients is exceedingly rare. Findlay et al 12 have estimated that secondary cutaneous involvement occurs with an incidence of less than 5% in disseminated aspergillosis.
As both patients reported here had no visible signs of skin damage before cutaneous involvement with Aspergillus species occurred, it is very likely that they both had secondary cutaneous involvement from dissemination of a systemic infection. However, in both of these patients skin involvement occurred as the first clinical manifestation of disseminated disease.
Khardori et al 9 described five cases of primary cutaneous aspergillosis or Rhizopus infection in immunosuppressed patients with cancer. All these infections were characterized by erythematous maculae that became purpuric and progressed rapidly in size. Four out of five of these lesions developed into hemorrhagic, necrotizing ulcers. Therefore, a rapidly growing lesion with an area of central necrosis seems to be a typical clinical manifestation of cutaneous Aspergillus involvement. In contrast to the patients reported here, in immunocompetent patients with cutaneous Aspergillus infection, these lesions appear as small, red discrete papules, sometimes with a pustule in the centre of the papule. When the pustule is opened purulent material can be recovered. 13 We were unable to detect antibodies against Aspergillus species or Aspergillus-antigen in either of our patients. This phenomenon has also been reported by Saugier-Veber et al 5 and is due to the profound immunosuppression, to irregular and transient excretion of Aspergillus-antigen and/or the formation of undetectable immune complexes. 14 These results emphasize the difficulty in diagnosing Aspergillus infection in immunosuppressed patients using serological methods. Recently, more sensitive diagnostic tests based on the detection of fungal cell wall components and Aspergillus-specific DNA sequences have been developed. The first clinical data in BMT patients indicate that this method has very high sensitivity and specificity. 15, 16 Therefore, use of PCR in early detection of fungus infection seems to be extremely useful.
It is important to note that in patient No. 1 the first clinical signs of pulmonary Aspergillosis were seen as late as 8 days after the appearance of the first skin lesion. At this time conventional chest X-ray was normal. This indicates that Aspergillus infection is difficult to diagnose on conventional chest X-ray. In neutropenic patients particularly, high resolution computed tomography (HRCT) of the chest has a much higher sensitivity in detection of pulmonary infiltrates and should be performed if there is any suspicion of pulmonary Aspergillus infection. 17 It is important to note that in our patients cutaneous Aspergillus infection developed and progressed despite prompt and appropriate antimycotic therapy. Resistance testing of the Aspergillus fumigatus against amphotericin B isolated from patient No. 1 showed that this Aspergillus species was fully sensitive to amphotericin B in vitro. As reported earlier 18 this clinical outcome highlights the importance of the presence of neutrophil leukocytes and the probably low efficacy of amphotericin B during neutropenia. Alternative therapeutic options consist of the use of high-dose liposomal amphotericin B or the newer azole drugs such as itraconazole or voriconazole. Liposomal amphotericin B offers the advantage of less toxicity than amphotericin B. Therefore use of high-dose liposomal amphotericin B might be appropriate.
Secondary Aspergillus infection of the skin is possible without visible trauma and even in the absence of clinically evident pulmonary aspergillosis. In the immunosuppressed patient cutaneous aspergillosis has to be considered as an extremely severe infectious complication with very poor outcome. Therefore, although rare, primary skin involvement appears to be a very bad prognosis factor, as it is a manifestation of infection dissemination. Despite antimycotic treatment in both patients there was only a very short time interval (9 days and 13 days) between first symptoms and death. The presence of erythema, progressing to a circular necrotic lesion in a patient with bone marrow aplasia should prompt antimycotic treatment. Administration of G-CSF together with the infusion of granulocytes should be considered. An intensive search for Aspergillus species or other fungal opportunistic organisms should be initiated. Because immunological methods for detection of Aspergillus species are unreliable it is important to use direct histological examination and culture of the infected tissue to establish the diagnosis of an invasive Aspergillus skin infection. The first clinical data indicate that PCR screening for detection of Aspergillus or other fungus DNA might be very useful in early detection of an Aspergillus infection.
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Further studies are necessary to evaluate the importance of such methods.
